Piper Says Mirati Now 'Prime' Biotech Takeout Candidate, Boosts Target
November 05, 2020 at 05:37 AM EST
Piper Sandler analyst Tyler Van Buren raised the firm's price target on Mirati Therapeutics to $260 from $210 and keeps an Overweight rating on the shares.
